Thomas G Wiggans Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Thomas Wiggans FMTX stock SEC Form 4 insiders trading

Thomas has made over 41 trades of the Forma Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently Thomas exercised 25,500 units of FMTX stock worth $510,255 on 15 August 2019.

The largest trade Thomas's ever made was exercising 25,500 units of Forma Therapeutics stock on 15 August 2019 worth over $510,255. On average, Thomas trades about 6,275 units every 22 days since 2008. As of 15 August 2019 Thomas still owns at least 65,166 units of Forma Therapeutics stock.

You can see the complete history of Thomas Wiggans stock trades at the bottom of the page.

What's Thomas Wiggans's mailing address?

Thomas's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7601 DUMBARTON CIRCLE, FREMONT, CA, 94555.

Insiders trading at Forma Therapeutics

Over the last 4 years, insiders at Forma Therapeutics have traded over $446,330 worth of Forma Therapeutics stock and bought 9,000,000 units worth $180,000,000 . The most active insiders traders include Capital Management, L.P.Ra ..., Peter Kolchinsky et Capital Management, L.P.Ra .... On average, Forma Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $10,575,905. The most recent stock trade was executed by Patrick F. Kelly on 13 April 2022, trading 15,000 units of FMTX stock currently worth $75,750.

What does Forma Therapeutics do?

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.

Forma Therapeutics executives and stock owners

Forma Therapeutics executives and other stock owners filed with the SEC include:

• Frank D. Lee,
  Pres, CEO & Director
• Dr. Patrick F. Kelly M.D.,
  Sr. VP & Chief Medical Officer
• Todd E. Shegog,
  Sr. VP & CFO
• Dr. Ifeyinwa Osunkwo M.D., M.P.H.,
  Sr. VP & Chief Patient Officer
• Andrew Littlehale MBA,
  Treasurer
• Brian Lesser,
  Sr. VP of Commercial
• Mary E. Wadlinger,
  Sr. VP of Corp. Affairs & Chief HR Officer
• Scott N. Boyle Ph.D.,
  VP of Bus. and Corp. Devel.
• Dr. Jeannette Potts J.D., Ph.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Dr. David N. Cook Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. John E. Bishop Ph.D.,
  Sr. VP & Chief Technology Officer
• Arturo Md Molina,
  Director
• Wayne A.I. Frederick,
  Director
• Steven Edward Hall,
  Director
• Todd Shegog,
  SVP, Chief Financial Officer
• Timothy P Clackson,
  Director
• Peter Wirth,
  Director
• Peter Kolchinsky,
  Director
• Paolo Paoletti,
  Director
• Mary E. Wadlinger,
  See Remarks
• Marsha Fanucci,
  Director
• Frank D. Lee,
  President and CEO
• Jeannette Potts,
  See Remarks
• David N Cook,
  SVP, Chief Scientific Officer
• Thomas G Wiggans,
  Director
• Capital Management, L.P.Ra ...,
  
• Biomedical Innovation Maste...,
  10% owner
• Selwyn M Md Vickers,
  Director
• Capital Management, L.P.Ra ...,
  
• John E Bishop,
  SVP, Chief Technology Officer
• Patrick F. Kelly,
  SVP, Chief Medical Officer
• Agustin Melian,
  EVP, Research & Development